France
Stilla Technologies, founded in 2013 and headquartered in France, is at the forefront of the biotechnology sector, specializing in next-generation genetic testing. The company has established itself as a pioneer in providing researchers and clinicians with an advanced Digital PCR solution, evident through their flagship naica® system that integrates the entire dPCR process onto a single chip.
The company's proprietary 6-color Digital PCR Platform surpasses traditional methods with its high sensitivity and multiplexing capabilities. This makes it particularly compelling for diverse applications such as cancer research, liquid biopsies, cell and gene therapies, infectious disease investigation, and environmental testing.
In its latest financial milestone, Stilla Technologies secured a $26.50M Series C investment on 22 February 2024, with support from a consortium of leading investors including IDInvest Partners, Kurma Partners, Illumina Ventures, and more. Their technological advancement aims to democratize Digital PCR as a staple in all life sciences sectors.
NimaGen